Who are Linzess's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Trulance, Linaclotide 72 micrograms, XOI, AJG555.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/linaclotide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Linzess — Competitive Intelligence Brief

Linzess (LINACLOTIDE) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Guanylate Cyclase-C Agonist [EPC]. Area: Metabolic.

marketed Guanylate Cyclase-C Agonist [EPC] Heat-stable enterotoxin receptor Metabolic Recombinant protein Live · refreshed every 30 min

Target snapshot

Linzess (LINACLOTIDE) — AbbVie. Linzess works by activating the heat-stable enterotoxin receptor to increase fluid secretion in the intestines.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Linzess TARGET	LINACLOTIDE	AbbVie	marketed	Guanylate Cyclase-C Agonist [EPC]	Heat-stable enterotoxin receptor	2012-01-01
Trulance	PLECANATIDE	Salix	marketed	Guanylate Cyclase-C Agonist [EPC]	Tumor necrosis factor	2017-01-01
Linaclotide 72 micrograms	Linaclotide 72 micrograms	Md Mehedi Shahriar	marketed	Guanylate cyclase-C agonist	GC-C (guanylate cyclase-C receptor)
XOI	XOI	Ironwood Pharmaceuticals, Inc.	marketed	Guanylate cyclase-C agonist	GC-C (guanylate cyclase-C)
AJG555	AJG555	EA Pharma Co., Ltd.	phase 3	Guanylate cyclase-C agonist	GC-C (guanylate cyclase-C)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Guanylate Cyclase-C Agonist [EPC] class)

AbbVie · 1 drug in this class
Salix · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Linzess — Competitive Intelligence Brief. https://druglandscape.com/ci/linaclotide. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab